The National Hemophilia Foundation (NHF) has been monitoring the latest information on the current coronavirus (2019-nCoV) as it pertains to the bleeding disorders community.
The Plasma Protein Therapeutics Association (PPTA) has issued a statement stating that the “2019-nCoV is not a concern for the safety of plasma protein therapies manufactured by PPTA member companies” at this time. The association stated that “existing manufacturing methods provide significant safety margins against the 2019-nCoV.” The complete statement is available here.
The European Haemophilia Consortium (EHC) is also monitoring the situation and referring concerned individuals to the European Centre for Disease Prevention and Control (ECDC), which has been following developments of the outbreak. The complete EHC statement is here.
World Federation of Hemophilia has also issued a statement on the coronavirus for people who may have concerns about travel to their 2020 World Congress in Kuala Lumpur, Malaysia. Read WFH’s statement here.
NHF holds the safety of people with bleeding disorders as its highest priority. We will continue to monitor the situation as it develops and will keep the community updated.
